Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France
Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)
Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…Opicapone management: A 2-year follow up real- life practice study
Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson’s Disease
Objective: To determine the rates of pharmacological treatment for neuropsychiatric symptoms (NPS) in patients with early Parkinson’s disease (PD), and identify predictors of under-treatment. Background:…Opicapone study in daily clinical practice. OPRA study
Objective: Improvement of off time and increase of ON time without dyskinesias at 6 months compared to the baseline situation. Secondary Endpoints: Determine the rate…Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting
Objective: Analyze effect of concomitant antiemetics and dopamine agonists (DA) on nausea and vomiting (N/V) in patients receiving apomorphine sublingual film (APL-130277; APL) for on-demand…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 32
- Next Page »